Rewiring immune function with precision engineered antibodies
Proteinea is a TechBio company transforming drug discovery and development by integrating advanced biotechnology with artificial intelligence. The company specializes in rational engineering of antibody Fc domains to enable context-specific immune tuning, enhanced half-life, and targeted biodistribution, combining AI-driven prediction with therapeutic insight. Proteinea's proprietary AI models and computational tools engineer next-generation antibodies with improved efficacy, safety, and manufacturability, with operations in Cambridge MA, Cairo, KAUST, and Munich.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2021
Create a free account to see which investors have funded this company.
Create Free Account
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
